Diagnostyka i leczenie niedoboru testosteronu u mężczyzn na podstawie wytycznych europejskich i amerykańskich towarzystw urologicznych
References
- Almeida O.P., Yeap B.B., Hankey G.J., Jamrozik K., Flicker L.: Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch. Gen. Psychiatry, 2008; 65: 283–289
- Araujo A.B., O’Donnell A.B., Brambilla D.J., Simpson W.B., Longcope C., Matsumoto A.M., McKinlay J.B.: Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab., 2004; 89: 5920–5926
- Baillargeon J., Urban R.J., Morgentaler A., Glueck C.J., Baillargeon G., Sharma G., Kuo Y.F..: Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin. Proc., 2015; 90: 1038–1045
- Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R., Miceli M., Mammi C., Piepoli M., Fini M., Rosano G.M.: Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol., 2009; 54: 919–927
- Chao J.K., Hwang T.I., Ma M.C., Kuo W.H., Liu J.H., Chen Y.P., Lin Y.C.: A survey of obesity and erectile dysfunction of men conscripted into the military in Taiwan. J. Sex. Med., 2011; 8: 1156–1163
- Corona G., Mannucci E., Fisher A.D., Lotti F., Petrone L., Balercia G., Bandini E., Forti G., Maggi M.: Low levels of androgens in men with erectile dysfunction and obesity. J. Sex. Med., 2008; 5: 2454–2463
- Corona G., Rastrelli G., Monami M., Melani C., Balzi D., Sforza A., Forti G., Mannucci E., Maggi M.: Body mass index regulates hypogonadism-associated CV risk: Results from a cohort of subjects with erectile dysfunction. J. Sex. Med., 2011; 8: 2098–2105
- Coviello A.D., Matsumoto A.M., Bremner W.J., Herbst K.L., Amory J.K., Anawalt B.D., Sutton P.R., Wright W.W., Brown T.R., Yan X., Zirkin B.R., Jarow J.P.: Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J. Clin. Endocrinol. Metab., 2005; 90: 2595–2602
- Crum-Cianflone N.F., Bavaro M., Hale B., Amling C., Truett A., Brandt C., Pope B., Furtek K., Medina S., Wallace M.R.: Erectile dys-function and hypogonadism among men with HIV. AIDS Patient Care STDS, 2007; 21: 9–19
- Dohle G.R., Arver S., Bettocchi C., Jones T.H., Kliesch S.: European association of urology guidelines on male hypogonadism: The 2018 update. https://uroweb.org/guideline/male-hypogonadism/ (05.02.2020)
- Finkle W.D., Greenland S., Ridgeway G.K., Adams J.L., Frasco M.A., Cook M.B., Fraumeni J.F.Jr, Hoover R.N.: Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 2014; 9: e85805
- Ford A.H., Yeap B.B., Flicker L., Hankey G.J., Chubb S.A., Handelsman D.J., Golledge J., Almeida O.P.: Prospective longitudinal study of testosterone and incident depression in older men: The Health In Men Study. Psychoneuroendocrinology, 2016; 64: 57–65
- Francomano D., Greco E.A., Lenzi A., Aversa A.: CAG repeat testing of androgen receptor polymorphism: Is this necessary for the best clinical management of hypogonadism? J. Sex. Med., 2013; 10: 2373–2381
- Garvey W.T., Mechanick J.I., Brett E.M., Garber A.J., Hurley D.L., Jastreboff A.M., Nadolsky K., Pessah-Pollack R., Plodkowski R., Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines: Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr. Pract., 2016; 22: 1–203
- Gianatti E.J., Dupuis P., Hoermann R., Zajac J.D., Grossmann M.: Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab., 2014; 99: 3821–3828
- Goodman N., Guay A., Dandona P., Dhindsa S., Faiman C., Cunningham G.R., AACE Reproductive Endocrinology Scientific Committee: American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of testosterone and cardiovascular risk. Endocr. Pract., 2015; 21: 1066–1073
- Halabi S., Collins E.G., Thorevska N., Tobin M.J., Laghi F.: Relationship between depressive symptoms and hypogonadism in men with COPD. COPD, 2011; 8: 346–353
- Hall S.A., Esche G.R., Araujo A.B., Travison T.G., Clark R.V., Williams R.E., McKinlay J.B.: Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J. Clin. Endocrinol. Metab., 2008; 93: 3870–3877
- Isidori A.M., Buvat J., Corona G., Goldstein I., Jannini E.A., Lenzi A., Porst H., Salonia A., Traish A.M., Maggi M.: A critical analysis of the role of testosterone in erectile function: From pathophysiology to treatment – A systematic review. Eur. Urol., 2014; 65: 99–112
- Jones T.H., Arver S., Behre H.M., Buvat J., Meuleman E., Moncada I., Morales A.M., Volterrani M., Yellowlees A., Howell J.D., Channer K.S., TIMES2 Investigators.: Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care, 2011; 34: 828–837
- Kamischke A., Kemper D.E., Castel M.A., Lüthke M., Rolf C., Behre H.M., Magnussen H., Nieschlag E.: Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur. Respir. J., 1998; 11: 41–45
- Kaplan S.A., Lee J.Y., O’Neill E.A., Meehan A.G., Kusek J.W.: Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male, 2013; 16: 169–172
- Kelsey T.W., Li L.Q., Mitchell R.T., Whelan A., Anderson R.A., Wallace W.H.: A validated age-related normative model for male total testosterone shows increasing variance but no decline after age 40 years. PLoS One, 2014; 9: e109346
- Kohn T.P., Louis M.R., Pickett S.M., Lindgren M.C., Kohn J.R., Pastuszak A.W., Lipshultz L.I.: Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil. Steril., 2017; 107: 351–357
- Malkin C.J., Pugh P.J., West J.N., van Beek E.J., Jones T.H., Channer K.S.: Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur. Heart J., 2006; 27: 57–64
- Martens H.F., Sheets P.K., Tenover J.S., Dugowson C.E., Bremner W.J., Starkebaum G.: Decreased testosterone levels in men with rheumatoid arthritis: Effect of low dose prednisone therapy. J. Rheumatol., 1994; 21: 1427–1431
- Mateo L., Nolla J.M., Bonnin M.R., Navarro M.A., Roig-Escofet D.: Sex hormone status and bone mineral density in men with rheumatoid arthritis. J. Rheumatol., 1995; 22: 1455–1460
- Mazzola C.R., Katz D.J., Loghmanieh N., Nelson C.J., Mulhall J.P..: Predicting biochemical response to clomiphene citrate in men with hypogonadism. J. Sex. Med. 2014; 11: 2302–2307
- Morgentaler A., Miner M.M., Caliber M., Guay A.T., Khera M., Traish A.M.: Testosterone therapy and cardiovascular risk: Advances and controversies. Mayo Clin. Proc., 2015; 90: 224–251
- Morgentaler A., Zitzmann M., Traish A.M., Fox A.W., Jones T.H., Maggi M., Arver S., Aversa A., Chan J.C., Dobs A.S., Hackett G.I., Hellstrom W.J., Lim P., Lunenfeld B., Mskhalaya G. i wsp.: Fundamental concepts regarding testosterone deficiency and treatment: International expert consensus resolutions. Mayo Clinic Proc., 2016; 91: 881–896
- Moskovic D.J., Araujo A.B., Lipshultz L.I., Khera M.: The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J. Sex. Med., 2013; 10: 562–569
- Mulhall J.P., Trost L.W., Brannigan R.E., Kurtz E.G., Redmon J.B., Chiles K.A., Lightner D.J., Miner M.M., Murad M.H., Nelson C.J., Platz E.A., Ramanathan L.V., Lewis R.W.: Evaluation and management of testosterone deficiency: AUA guideline. J. Urol., 2018; 200: 423–432
- Mulligan T., Frick M.F., Zuraw Q.C., Stemhagen A., McWhirter C.: Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int. J. Clin. Pract., 2006; 60: 762–769
- Muraleedharan V., Marsh H., Kapoor D., Channer K.S., Jones T.H..: Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur. J. Endocrinol., 2013; 169: 725–733
- Nieschlag E., Bouloux P.G., Stegmann B.J., Shankar R.R., Guan Y., Tzontcheva A., McCrary Sisk C., Behre H.M.: An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reprod. Biol. Endocrinol., 2017; 15: 17
- Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morley J.E., Schulman C., Wang C., Weidner W., Wu F.C.: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int. J. Androl., 2005; 28: 125–127
- Ohlander S.J., Varghese B., Pastuszak A.: Erythrocytosis following testosterone therapy. Sex. Med. Rev., 2017; 61: 1038–1045
- Pastuszak A.W., Badhiwala N., Lipshultz L.I. Khera M.: Depression is correlated with the psychological and physical aspects of sexual dysfunction in men. Int. J. Impot. Res., 2013; 25: 194–199
- Pugh P.J., Jones R.D., West J.N., Jones T.H., Channer K.S.: Testosterone treatment for men with chronic heart failure. Heart, 2004; 90: 446–447
- Ramasamy R., Scovell J.M., Kovac J.R., Lipshultz L.I.: Testosterone supplementation versus clomiphene citrate for hypogonadism: An age matched comparison of satisfaction and efficacy. J. Urol., 2014; 192: 875–879
- Rao P.M., Kelly D.M., Jones T.H.: Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat. Rev. Endocrinol., 2013; 9: 479–493
- Roberts C.K, Chen B.H., Pruthi S., Lee M.L.: Effects of varying doses of testosterone on atherogenic markers in healthy younger and older men. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2014; 306: R118–R123
- Saad F., Aversa A., Isidori A.M., Zafalon L., Zitzmann M., Gooren L.: Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur. J. Endocrinol., 2011; 165: 675–685
- Santos M.R., Sayegh A.L., Groehs R.V., Fonseca G., Trombetta I.C., Barretto A.C., Arap M.A., Negrão C.E., Middlekauff H.R., Alves M.J.: Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failure. Arq. Bras. Cardiol., 2015; 105: 256–264
- Sato Y., Tanda H., Kato S., Onishi S., Nakajima H., Nanbu A., Nitta T., Koroku M., Akagashi K., Hanzawa T.: Prevalence of major depressive disorder in self-referred patients in a late onset hypogonadism clinic. Int. J. Impot. Res., 2007; 19: 407–410
- Sharma R., Oni O.A., Chen G., Sharma M., Dawn B., Sharma R., Parashara D., Savin V.J., Barua R.S., Gupta K.: Association between testosterone replacement therapy and the incidence of DVT and pulmonary embolism: A retrospective cohort study of the veterans administration database. Chest, 2016; 150: 563–571
- Stanworth R.D., Akhtar S., Channer K.S., Jones T.H.: The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study. Eur. J. Endocrinol., 2013; 170: 193–200
- Sussman E.M., Chudnovsky A., Niederberger C.S.: Hormonal evaluation of the infertile male: Has it evolved? Urol. Clin. North Am., 2008; 35: 147–155
- Taylor F., Levine L.: Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: Efficacy and treatment cost. J. Sex. Med., 2010; 7: 269–276
- Vandenput L., Mellström D., Karlsson M.K., Orwoll E., Labrie F., Ljunggren Ö., Ohlsson C.: Serum estradiol is associated with lean mass in elderly Swedish men. Eur. J. Endocrinol., 2010; 162: 737–745
- Vigen R., O’Donnell C.I., Barón A.E., Grunwald G.K., Maddox T.M., Bradley S.M., Barqawi A., Woning G., Wierman M.E., Plomondon M.E., Rumsfeld J.S., Ho P.M.: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 2013; 310: 1829–1836
- Wang C., Nieschlag E., Swerdloff R., Behre H.M., Hellstrom W.J., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morales A., Morley J.E., Schulman C., Thompson I.M., Weidner W., Wu F.C. i wsp.: Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur. Urol., 2009; 55: 121–130
- Wenker E.P., Dupree J.M., Langille G.M., Kovac J., Ramasamy R., Lamb D., Mills J.N., Lipshultz L.I.: The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. J. Sex. Med., 2015; 12: 1334–1337
- Wiehle R., Cunningham G.R., Pitteloud N., Wike J., Hsu K., Fontenot G.K., Rosner M., Dwyer A., Podolski J.: Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: Pharmacodynamics and pharmacokinetics. BJU Int., 2013; 112: 1188–1200
- Wiehle R.D., Fontenot G.K., Michael M.S., Willett M.S., Garcia W.D., Podolski J.S.: Enclomiphene citrate stimulates serum testosterone in men with low testosterone within 14 days. J. Men’s Health, 2014; 11: 196–205
- Wiehle R.D., Fontenot G.K., Wike J., Hsu K., Nydell J., Lipshultz L., ZA-203 Clinical Study Group: Enclomiphene citrate stimulates testosterone production while preventing oligospermia: A randomized phase II clinical trial comparing topical testosterone. Fertil. Steril., 2014; 102: 720–727
- World Health Organization Task Force on Methods for the Regulation of Male Fertility: Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril., 1996; 65: 821–829
- Wu F.C., Tajar A., Beynon J.M., Pye S.R., Silman A.J., Finn J.D., O’Neill T.W., Bartfai G., Casanueva F.F., Forti G., Giwercman A., Han T.S., Kula K., Lean M.E., Pendleton N. i wsp.: Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med., 2010; 363: 123–135
- Xu L., Freeman G., Cowling B.J., Schooling C.M.: Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med., 2013; 11: 108
- Zitzmann M., Mattern A., Hanisch J., Gooren L., Jones H., Maggi M.: IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J. Sex. Med., 2013; 10: 579–588
DOI: https://doi.org/10.5604/01.3001.0014.8308 | Journal eISSN: 1732-2693
Language: English
Page range: 217 - 228
Submitted on: Feb 6, 2020
Accepted on: Sep 28, 2020
Published on: Apr 7, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2021 Jarosław Mielewczyk, Elżbieta Świętochowska, Zofia Ostrowska, Igor Miczek, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.